EXSCEL trial

The EXSCEL trial assessed the CV safety of once weekly exenatide versus placebo in >14,000 patients with T2D, the majority of which had experienced a previous CV event. 4 This module details the CV endpoints and safety results from the trial.

EXSCEL trial
Rate this content
  • EXSCEL trial
  • EXSCEL: study design
  • EXSCEL: prespecified hierarchical testing strategy
  • EXSCEL: hierarchical testing outcomes
  • EXSCEL: baseline characteristics
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go